MGX insiders were on both sides of the trade this year. Buys came to roughly $23,000 (one buyer), sales to $44,000 (four sellers).
The largest purchase came from Reid Laurence (Director), about $23,000.
On the institutional side, 43 funds reported holding MGX at the end of Q2 2026, and more funds sold than bought. Zooming out by quarter: Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Reid Laurence | Director | Buy | 19,883 | $1.17 | $23K | SEC |
| Sep 11, 2026 | Reid Laurence | Director | Buy | 117 | $1.18 | $138 | SEC |
| Sep 10, 2026 | Wein Matthew | Officer | Sell | 358 | $1.16 | $415 | SEC |
| Sep 10, 2026 | Irish Jian | Officer | Sell | 2,140 | $1.16 | $2K | SEC |
| Sep 10, 2026 | Wapnick Pamela | CFO | Sell | 1,911 | $1.16 | $2K | SEC |
| Jun 10, 2026 | Wapnick Pamela | CFO | Sell | 2,884 | $1.30 | $4K | SEC |
| Jun 10, 2026 | Irish Jian | Officer | Sell | 3,737 | $1.30 | $5K | SEC |
| Jun 10, 2026 | Wein Matthew | Officer | Sell | 558 | $1.30 | $725 | SEC |
| Mar 9, 2026 | Wapnick Pamela | CFO | Sell | 1,581 | $1.60 | $3K | SEC |
| Mar 9, 2026 | Wein Matthew | Officer | Sell | 482 | $1.60 | $771 | SEC |
| Mar 9, 2026 | Irish Jian | CEO | Sell | 1,607 | $1.60 | $3K | SEC |
| Dec 8, 2025 | Thomas Brian C. | Director | Sell | 3,830 | $1.77 | $7K | SEC |
| Dec 8, 2025 | Wein Matthew | Officer | Sell | 199 | $1.77 | $352 | SEC |
| Dec 8, 2025 | Wapnick Pamela | CFO | Sell | 1,576 | $1.77 | $3K | SEC |
| Dec 8, 2025 | Irish Jian | CEO | Sell | 1,602 | $1.77 | $3K | SEC |
In the last 12 months Metagenomi Therapeutics, Inc. insiders made open-market purchases worth about $23,000 and sales worth about $44,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in MGX was filed on 2026-09-11.
43 investment managers reported holding MGX in SEC Form 13F filings for Q2 2026.
No congressional trades in MGX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).